Kurzfassung

A phase 2a proof of concept study comparing three doses of an oral tablet formulation of LEO 32731 with a corresponding placebo in patients with moderate to severe psoriasis vulgaris A multi-centre, prospective, randomized, double-blind, 4-arm, placebo-controlled, parallelgroup study with 16 weeks twice times daily oral treatment